JP Morgan Maintains Overweight on Bristol-Myers Squibb, Raises Price Target to $73

JP Morgan analyst Chris Schott maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $67 to $73.